



## **Lifetime Treatment of Schizophrenia: What Helps and What Doesn't for Patients and Their Significant Others**

Ira D. Glick, M.D.  
Professor Emeritus,  
Department of Psychiatry and Behavioral Sciences  
Stanford University School of Medicine



12/26/2017

# Disclosures

---

- Equity in Johnson&Johnson
- Serves on Advisory Boards, on Speakers Bureaus, and as Consultant for NIMH and Industry
- Oversees clinical research sites at Stanford University School of Medicine and Pacific Research Partners, Oakland, CA



## Message

---

- Psychiatric disorders are like medical diseases and should be mostly treated as such



## Objectives

---

- A “walk” through:
  - Modern psychiatry
  - Modern psychopharmacology
  - Modern diagnosis and treatment of schizophrenia



## Kartagener's Syndrome and Schizophrenia

---

- Glick ID, Graubert DN: Kartagener's syndrome and schizophrenia: Report of a case with chromosomal studies, *Am J Psychiatry* 121:603-605, 1954



# Schizophrenia in Siblings Reared Apart

---

Glick ID, Setleis H, Woerner MH, Pollack M: Schizophrenia in siblings reared apart: A case report. *Am J Psychiatry* 124:236-240, 1967.



## The “Sick” Family and Schizophrenia?

---

Glick ID: The "sick" family and schizophrenia - cause and effect? Supplement, *Dis Nerv Syst* 29:129-132, May 1968.



## Auditory Hallucinations with Antidepressant Medication

---

Hauptman B, Glick ID: Auditory hallucinations with imipramine. *J Hillside Hosp* 17:32-34, 1968



# Childhood Asoiality in Schizophrenia

---

Glick ID, Winstead D: Childhood asociality in the differential diagnosis of schizophrenia with drug abuse vs. psychosis with drug intoxication. *Psychiat Quart* 47:208-217, 1973.



# Short vs Long Hospitalization for Schizophrenia

---

Glick ID, Hargreaves WA: Psychiatric Hospital Treatment for the 1980s: A Controlled Study of Short Versus Long Hospitalization. Lexington, Mass., Lexington Press, 1979.



# Family Presence and Treatment for Schizophrenia

---

- Gould E, Glick ID: The effects of family presence and family therapy on outcome of hospitalized schizophrenic patients. *Family Process* 16:503-510, 1977.







## Prestimulus Effects on Startle Reflex for Schizophrenia

---

- Braff D, Stone C, Callaway E, Geyer M, Glick ID, Bali L: Prestimulus effects on human startle reflex in normals and schizophrenics. *Psychophysiology* 15:339-343, 1978.



## Premorbid Asocial Adjustment and Outcome in Schizophrenia

---

Drues J, Hargreaves WA, Glick ID, Klein DF: Premorbid asocial adjustment and outcome in schizophrenia. *J Nerv & Ment Dis* 166:881-884, 1978.



## New Drug Treatment for Premenstrual Exacerbation in Schizophrenia

---

Glick ID, Stewart D: A new drug treatment for premenstrual exacerbation of schizophrenia. *Comprehensive Psychiatry* 21:281-287, 1980



# Molindone vs HPI for Schizophrenia

---

- Binder R, Glick ID, Rice M: A comparative study of parenteral molindone and haloperidol in the acutely psychotic patient. *J Clin Psychiatry* 42:203-206, 1981.



# Psychoeducation for Schizophrenia

---

Greenberg L, Fine SB, Cohen C, Larson K, Michaelson A, Rubinton P, Glick, ID: An interdisciplinary psychoeducation program for schizophrenic patients and their families in an acute care setting. *Hospital & Community Psychiatry*, 39:277-282, 1988



# Inpatient Family Intervention for Schizophrenia

---

Spencer JH, Glick ID, Haas GL: A randomized clinical trial of inpatient family intervention, III. Overall effects at followup for the entire sample. *Am J Psychiatry*, 145:1115-1121, 1988.

Glick ID, Spencer JH, Clarkin JF, et al: A Randomized Clinical Trial of Inpatient Family Intervention IV. Followup Results for Subjects with Schizophrenia. *Schizophrenia Research*, 3:187-200, 1990.



## ↑ **Between Patient and Doctor – Quality of Care for Schizophrenia**

---

Glick ID, Showstack JA, Cohen C, Klar HM: Between Patient and Doctor: Improving the Quality of Care for Serious Mental Illness. *Bulletin of the Menninger Clinic*, 53:193-202, 1989.



## **Gender and Schizophrenia Outcome**

---

- Haas GL, Glick ID, Clarkin JF, et al: Gender and schizophrenia outcome: A clinical trial of an inpatient family intervention. *Schizophr Bull*, 16:277-292, 1990.





## Effectiveness in Psychiatric Care

---

Glick ID: Improving treatment for the severely mentally ill: Implications of the decade-long Italian psychiatric reform. *Psychiatry*, 53:316-323, 1990.

Glick ID, Burti L, Suzuki K, Sacks M: Effectiveness in psychiatric care: IV. Achieving effective medication management for major affective disorder. *Psychopharmacology Bulletin* 28:257-259, 1992.



# Inpatient Care for Schizophrenia in a General Hospital

---

Olfson M, Glick ID and Mechanic D: Inpatient treatment of schizophrenia in general hospitals. *Hospital & Community Psychiatry*, 44:40-44, 1993.



# Improving Outpatient Treatment for Seriously Mentally Ill

---

- Hanrahan M, Glick ID: Improving outpatient treatment for severely mentally ill persons: Doing the right thing. *Administration Policy in Mental Health*, 23:459-463, 1996.



# Treatment Strategies in Schizophrenia: Maintenance Therapy for Schizophrenia

---

Schooler NR, Keith SJ, Severe JB, Matthews SM, Bellack AS, Glick ID:  
Relapse and rehospitalization during maintenance treatment of schizophrenia:  
The effects of dose reduction and family treatment. *Archives of Gen Psych*,  
54:453-463, 1997.

Mueser KT, Sengupta A, Schooler NR, Bellack AS, Xie H, Glick ID, Keith SJ:  
Family treatment and medication dosage reduction in schizophrenia: effects on  
patient social functioning, family attitudes, and burden. *J Consulting &  
Clinical Psychology*; 69:3-12, 2001.





## New Algorithm for Treating Schizophrenia

---

Pearsall R, Glick ID, Pickar D, Suppes T, Tauscher J, Jobson KO: A new algorithm for treating schizophrenia. *Psychopharmacology Bulletin*, 34:349-353, 1998.



## Lithium Augmentation for Schizophrenia

---

Schultz SC, Thompson P, Jacobs M, Ninnan PT, Robinson D, Weiden P, Yadalam K, Glick ID: Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients. *J Clin Psychiatry*, 60:366-372, 1999.



# Psychopharmacologic Treatment Strategies for Schizophrenia

---

Glick ID, Suppes T, DeBattista C, Hu R, Marder S: Clinical update: psychopharmacological treatment strategies for depression, bipolar disorder and schizophrenia. *Annals Internal Medicine* 134:47-60, 2001.



# Treatment of Schizophrenia: Comparison of Antipsychotics

---

- Glick ID, Lemmens P, Vester-Blokland E: Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents. *International Clinical Psychopharmacology*, 16:265-274, 2001.





## Improving Clinical Trials of APs

---

Klein DF, Glick ID et al: Improving clinical trials: American Society of Clinical Psychopharmacology recommendations. *Archives of General Psychiatry*, 59:72-278, 2002.



## Treatment with Atypical Antipsychotics: New Disorders

---

Glick ID, Murray SF, Vasudevan P, Marder SR, Hu RJ: Treatment with atypical antipsychotics: new indications and new populations. *J Psychiatric Research* 35:187-191, 2001.



## Time to Discontinuation, Relapse and Compliance with Antipsychotics

---


Glick ID, Berg PH: Time to study discontinuation, relapse and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders. *International Clin Psychopharm* 17:65-68, 2002.



# Patient and Family Support Organizations for Treatment for Schizophrenia

---

Glick ID, Dixon L: Patient and family support organization services should be included as part of treatment for chronic psychiatric illness. *J Psychiatric Practice*, 8:63-69, 2002.



# Meta-Analysis of Relative Effectiveness of Antipsychotics

---

Davis JM, Chen N, Glick ID: A meta-analysis of the efficacy of second-generation antipsychotics. *Archives of General Psychiatry* 60:553-564, 2003.

Davis JM, Chen N, Glick I. Letter: Subjecting meta-analyses to closer scrutiny: little support for differential efficacy among second-generation antipsychotics at equivalent doses. *Arch Gen Psychiatry* 2006; 63:935-938.



# Overview of Schizophrenia Treatment

---

- Jibson MD, Glick ID, Tandon RT: Schizophrenia and other psychotic disorders. *Focus* 2:17-30, 2004



# Treatment of Schizophrenia: From Asylum to Intensive Care

---

Glick ID, Carter WG, Tandon R: A paradigm for treatment of inpatient psychiatric disorders: from asylum to intensive care. *J Psychiatric Practice* 9:1-5, 2003.



# Cloz vs Olanz for Schizophrenia: Effects on Suicide and Suicidal Behavior

---

Glick ID, Zaninelli R, Hsu C, et al: Patterns of concomitant psychotropic medication use during a two year study comparing clozapine and olanzapine for the prevention of suicidal behavior. *J Clinical Psychiatry* 65:679-685, 2004.



## First Episode Schizophrenia and Substance Use Disorder

---

Green AI, Tohen MF, Hamer RM, et al: First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. *Schizophrenia Research* 66:125-135, 2004.

McEvoy JP, Johnson J, Perkins D, Lieberman JA, Hamer RM, Keefe RSE, Tohen M, Glick ID: Insight in first episode psychosis. *Psychological Medicine* 60:1385-1394, 2006.



## Zip vs Olanz for Schizophrenia

---

Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO: Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. *Am J Psychiatry* 161:1837-1847, 2004.





## Long-term Maintenance Rx: Oral vs LAIs

---

Glick ID, Marder SR: Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. *J Clinical Psychiatry* 66:638-641, 2005.



## Aripip: Positive and Negative Effects

---

- Glick ID, Duggal V, Hodulik C: Aripiprazole as a dopamine partial agonist: positive and negative effects. *J Clinical Psychopharmacology* 26:101-103, 2006.



## Risperidone vs Other APs for Chronic Schizophrenia

---

Glick ID, Shkedy Z, Schreiner A: Differential early onset of therapeutic response with risperidone versus conventional antipsychotics in patients with chronic schizophrenia. *International Clinical Psychopharm*, 21:261-266, 2006.



## Quality of life: HPI vs Olanz

---

Strakowski SM Johnson JL, DelBello MP, Hamer M, Green AI, Tohen M, Lieberman JA, Glick ID, Patel JK. Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. *Schizophrenia Resear*

Green AI, Lieberman JA, Hamer RM, Glick ID, et al: Olanzapine and haloperidol in first episode psychosis: Two-year data. *Schizophrenia Research* 86:234-243, 2006 *ch* 78:161-169, 2005.





## CATIE

Glick ID: Understanding the results of CATIE in the context of the field. *CNS Spectrums* 11:40-47, 2006.

Glick ID, Pham D, Davis JM: Concomitant medications may not improve outcome of antipsychotic monotherapy for stabilized patients with nonacute schizophrenia. *J Clinical Psychiatry* 67:1261-1265, 2006





## First Generation Antipsychotics

---

Glick ID, He X, Davis JM: First-generation antipsychotics: current status.  
*Primary Psychiatry* 13:51-58, 2006



## Metabolic Impact: Switching to Aripip

---

Kim SH, Ivanova O, Glick ID, Reaven G: Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study. *J Clin Psychopharmacology*, 27:365-368, 2007



## Design -- Issues Related to Outcome of Antipsychotic Trials

---

Davis JM, Chen N, Glick ID: Issues that may determine the outcome of antipsychotic trials: Industry sponsorship and extrapyramidal side effect. *Neuropsychopharmacology*, 33:971-975, 2008.



# Schizophrenia with Comorbid OCD

---

Glick ID, Poyurovsky M, Ivanova O, Koran L: Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms. *J Clinical Psychiatry*, 69:1856-1859, 2008.



# Aripip and Schizophrenia Symptoms

---

Janicak PG, Glick ID, Marder SR et al: The efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled analysis from five short-term studies. *J Clinical Psychiatry*, 70:25-35, 2008.



## New Antipsychotic Agents

---

- Glick ID, Peselow ED: New antipsychotic agents. *Primary Psychiatry*, 15:57-64, 2008.



## Mood Stabilizers for Schizophrenia

---


Glick ID, Bosch J, Casey DE: A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive. *J Clin Psychopharmacology*, 29:267-271, 2009.



# Onset and Persistence of Antipsychotic Response

---

- Glick ID, Bossie CA, Alphs L, Canuso CM: The onset and persistence of antipsychotic response in patients with schizophrenia. *J Clinical Psychopharm*, 29:542-7, 2009.





## Role of Family in Maintenance Treatment

---

- Glick ID, Janowsky A, Hays S: The role of the family and improvement in treatment maintenance, adherence, and outcome for schizophrenia. *J Clinical Psychopharmacology*, 31:82-85, 2011.



## Clinical Trial Design: Lessons from the CATIE Study

---

Kraemer C, Glick ID, Klein DF: Clinical trials design lessons from the CATIE study. *American J Psychiatry*, 166:1222-1228, 2009.



# Designing Outcome Studies for Antipsychotics

---

Altamura AC, Glick ID: Designing outcome studies to determine efficacy and safety of antipsychotics for 'real world' treatment of schizophrenia. International Journal of Neuropsychopharmacology. 2010, 13:971-973.



## Mid and Long-term Effectiveness of Antipsychotics for Schizophrenia

---

Glick ID, Correll C, Altamura C, Davis J et al: Mid and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: A data-driven, personalized clinical approach. *Journal Clinical Psychiatry*, 2011; 72:1616-1627.



## Concomitant Meds for Schizophrenia

---

Chakos M, Patel J, Rosenheck R, Glick ID, et al: Concomitant Psychotropic Medication Use During Treatment of Schizophrenia Patients; Longitudinal Results from the CATIE Study. *Clinical Schizophrenia & Related Psychosis*, 2011, 5: 124-134.



## Iloperidone for Schizophrenia

---

Weiden P, Citrone L, ... Glick I et al: A Trial Evaluating Gradual – or Immediate –Switch Strategies from Risperidone, Olanzapine or Aripiprazole to Iloperidone in Patients with Schizophrenia Schizophrenia Research, 2014, 153:160-8.

Citrone L, Weiden P, Glick I et al: Switching to Iloperidone: An Omnibus of Clinically Relevant Observations from a 12-Week Open Label RCT in 500 Persons with Schizophrenia, Clinical Schizophrenia and Related Psychoses, 2014, 3:1-38.



## Switching to Aripip from Other APs

---

Stroup TS, Byerly MJ . . . Glick I D et al: Effects of Switching from Olanzapine, Quetiapine, and Risperidone to Aripiprazole on 10-year Coronary Heart Disease Risk and Metabolic Syndrome Status: Results from a randomized controlled trial, Schizophrenia Res, 2013, 146:190-5.



# Antipsychotic Medication for Schizophrenia for a Lifetime

---

Glick I D, Davis J M , Zamora D et al: Should Antipsychotic Medications for Schizophrenia Be Given for a Lifetime? A Naturalistic Long-term Followup Study, J Clin. Psychopharm, 2017, 37:125-130.



# Future of Medicine

---

Obermeyer Z, Lee TH. Lost in thought – The limits of the human mind and the future of medicine. N Engl J Med 377:1209-1211.



# How Treatment and Medicine has Changed

---

- Future of medicine: Us (the doctors) plus new tech



## Summary and Conclusion

---

- “There is nothing so constant in life, as change – keep learning and keep moving!”



## Message

---

- Psychiatric disorders are like medical diseases and should be mostly treated as such





## Mentors-Collaborators-Students

- Donald Klein, Leon Epstein, Alan Schatzberg,
- William Hargreaves, Robert Michels, John Clarkin, John Davis, Nina Schoolar, Carol Nadelson
- Collaborators – Gretchen Haas, Joan Drues
- Trainees/students – too numerous to mention
- Support staff – Diana Pham
- WITH MORE “THANKS” THAN CAN BE EXPRESSED IN A SLIDE. . .

